logo
Twitter
Discord
Email
logo
PepGen Inc.

PepGen Inc.

NASDAQ•PEPG
CEO: Dr. James G. McArthur Ph.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2022-05-06
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.
Contact Information
321 Harrison Avenue, 8th Floor, Boston, MA, 02118, United States
781-797-0979
pepgen.com
Market Cap
$374.68M
P/E (TTM)
-1.9
37
Dividend Yield
--
52W High
$7.80
52W Low
$0.88
52W Range
66%
Rank58Top 85.6%
2.3
F-Score
Modified Piotroski Analysis
Based on 6-year fundamentals
Weak • 2.3 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2020-2025

Financial Dashboard

Q3 2025 Data

Revenue

$0.00+0.00%
4-Quarter Trend

EPS

$0.55-183.33%
4-Quarter Trend

FCF

-$19.36M-20.01%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Cash Position Strengthened Significantly Net cash provided by financing activities reached $108.2M for nine months, driven by 2025 Offering; cash runway extends into H2 2027.
PGN-EDODM1 Clinical Data Positive Phase 1 trial reported 53.7% mean splicing correction for PGN-EDODM1 at 15 mg/kg dose level; dose escalation concluded.
Discontinued DMD Program Efforts Voluntarily ceased development of PGN-EDO51 for DMD in May 2025; winding down all related research and development activities.

Risk Factors

Significant Net Loss Continues Nine months net loss totaled $71.3M, an increase from $67.7M last year; accumulated deficit reached $342.8M.
Substantial Future Funding Needed Expect expenses to increase substantially; significant additional funding required to advance PGN-EDODM1 past 2026 data readouts.
Shareholder Litigation Exposure Facing putative shareholder class action lawsuit alleging material misrepresentations regarding the discontinued PGN-EDO51 program.
Third-Party Manufacturing Reliance Rely heavily on single-source third parties for manufacturing and clinical testing; performance failure risks supply chain disruption.

Outlook

Advance PGN-EDODM1 Development Focus development efforts on PGN-EDODM1 for DM1; plan to report data from FREEDOM2 study in first quarter 2026.
Stock Option Repricing Completed Approved repricing 3.56M stock options to $4.53 exercise price in November 2025; compensation expense impact pending determination.
Continue EDO Platform Research Maintain research efforts for other potential investigational drugs addressing various neuromuscular and neurologic disorders.

Peer Comparison

Revenue (TTM)

C4 Therapeutics, Inc.CCCC
$30.11M
-10.6%
Nuvectis Pharma, Inc.NVCT
$26.80M
-753.4%
Nkarta, Inc.NKTX
$9.03M
-14.3%

Gross Margin (Latest Quarter)

C4 Therapeutics, Inc.CCCC
100.0%
+13.4pp
Cardiff Oncology, Inc.CRDF
100.0%
+0.0pp
PepGen Inc.PEPG
0.0%
+0.0pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
CYBN$413.02M-2.5-51.8%15.9%
PEPG$374.68M-1.9-84.1%9.2%
ACHV$298.11M-3.7-196.7%19.1%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
N/M
Revenue Volatile
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Next earnings:Feb 23, 2026
|
EPS:-$0.38
|
Revenue:-
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 12, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $0.55-183.3%
    N/A

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 7, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.70-19.5%
    N/A

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 8, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.92+46.0%
    N/A

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 24, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-2.85+13.6%
    N/A

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 7, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.66-32.7%
    N/A

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 8, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.87+6.1%
    N/A

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 14, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.63-8.7%
    N/A

  • Form 10-K/A - FY 2023

    Period End: Dec 31, 2023|Filed: Mar 29, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-3.30+25.3%
    N/A